Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug.
Tietze
Lutz F
LF
Institut für Organische Chemie der Georg-August-Universität Göttingen, Tammannstrasse 2, 37077 Göttingen, Germany. ltietze@gwdg.de
Feuerstein
Tim
T
Fecher
Anja
A
Haunert
Frank
F
Panknin
Olaf
O
Borchers
Ulrich
U
Schuberth
Ingrid
I
Alves
Frauke
F
D000818:Animals; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000473:pathology; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003521:Cyclopropanes / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D057487:Enzyme Therapy; D005260:Female; D005697:Galactosides / Q000737:chemistry; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D020128:Inhibitory Concentration 50; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009369:Neoplasms / Q000188:drug therapy*; D011355:Prodrugs / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D014407:Tumor Cells, Cultured; D001616:beta-Galactosidase
C445728:1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one; D003521:Cyclopropanes; D005697:Galactosides; D018796:Immunoconjugates; D007211:Indoles; D011355:Prodrugs; D001616:beta-Galactosidase